Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review

被引：49

作者：

Aly, Abdalla ^{[1
]}

Ronnebaum, Sarah ^{[2
]}

Patel, Dipen ^{[2
]}

Doleh, Yunes ^{[1
]}

Benavente, Fernando ^{[1
]}

机构：

[1] AstraZeneca, Gaithersburg, MD 20878 USA

[2] Pharmerit, Bethesda, MD 20814 USA

来源：

HEPATIC ONCOLOGY | 2020年 / 7卷 / 03期

关键词：

epidemiology; hepatocellular carcinoma; pharmacoeconomics; risk factors; staging; QUALITY-OF-LIFE; RACE/ETHNICITY-SPECIFIC DISPARITIES; HEPATITIS-C VIRUS; RESOURCE UTILIZATION HCRU; ADVANCED LIVER-DISEASE; HEALTH-CARE COSTS; UNITED-STATES; TRANSARTERIAL CHEMOEMBOLIZATION; RISK-FACTORS; INPATIENT MORTALITY;

D O I：

10.2217/hep-2020-0024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To describe the epidemiologic, humanistic and economic burdens of hepatocellular carcinoma (HCC) in the USA. Materials & methods: Studies describing the epidemiology and economic burden from national cohorts, any economic models, or any humanistic burden studies published 2008-2018 were systematically searched. Results: HCC incidence was 9.5 per 100,000 person-years in most recent data, but was similar to 100-times higher among patients with hepatitis/cirrhosis. Approximately a third of patients were diagnosed with advanced disease. Patients with HCC experienced poor quality of life. Direct costs were substantial and varied based on underlying demographics, disease stage and treatment received. Between 25-77% of patients did not receive surgical, locoregional or systemic treatment. Conclusion: Better treatments are needed to extend survival and improve quality of life for patients with HCC.

引用

页数：18

共 50 条

[21] THE ECONOMIC AND HUMANISTIC BURDEN OF DYSTROPHIC EPIDERMOLYSIS BULLOSA (DEB): A SYSTEMATIC LITERATURE REVIEW
Harricharan, S.
Richard, M. E.
Roman, J.
Forsythe, A.
VALUE IN HEALTH, 2021, 24 : S221 - S221
[22] ECONOMIC AND HUMANISTIC BURDEN IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY - A SYSTEMATIC LITERATURE REVIEW
Spoorendonk, J. A.
Gulser, Sahbaz S.
Arca, E.
Hurst, M.
Zema, C.
Contente, M.
Krause, T.
VALUE IN HEALTH, 2022, 25 (12) : S374 - S374
[23] Economic and Humanistic Burden Among Individuals With CKD in the United States: A Systematic Literature Review
Osenenko, Katherine M.
Chatterjee, Satabdi
Ray, Saurabh
Li, Tina
Donato, Bonnie M.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 254 - 254
[24] A SYSTEMATIC LITERATURE REVIEW OF THE HUMANISTIC BURDEN OF MULTIPLE MYELOMA
Rizzo, M.
Xu, Y.
Panjabi, S.
Iheanacho, I.
VALUE IN HEALTH, 2014, 17 (07) : A537 - A537
[25] EPIDEMIOLOGY, ECONOMIC BURDEN, AND HUMANISTIC BURDEN IN MULTIPLE SCLEROSIS SPASTICITY (MSS): A SYSTEMATIC LITERATURE REVIEW (SLR)
Drachenberg, C.
Nazar, G.
Pushkarna, D.
Viswanathan, H.
Fazeli, M. S.
VALUE IN HEALTH, 2023, 26 (12) : S247 - S247
[26] Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review
Min Huang
Amin Haiderali
Grace E. Fox
Andrew Frederickson
Javier Cortes
Peter A. Fasching
Joyce O’Shaughnessy
PharmacoEconomics, 2022, 40 : 519 - 558
[27] HUMANISTIC AND ECONOMIC BURDEN OF X-LINKED HYPOPHOSPHATEMIA (XLH): A SYSTEMATIC LITERATURE REVIEW
Patel, R.
Kumar, J.
Gupta, J.
Narayanan, S.
VALUE IN HEALTH, 2018, 21 : S307 - S307
[28] CLINICAL, HUMANISTIC, AND ECONOMIC BURDEN IN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP): A SYSTEMATIC LITERATURE REVIEW
Thompson, J. C.
Xin, Q.
Boing, E.
VALUE IN HEALTH, 2022, 25 (12) : S486 - S486
[29] A SYSTEMATIC LITERATURE REVIEW OF THE ECONOMIC AND HUMANISTIC BURDEN OF CARDIAC AL AMYLOIDOSIS (AL-A)
Thompson, J. C.
Scott, D. A.
Teynor, M.
VALUE IN HEALTH, 2022, 25 (01) : S185 - S185
[30] Humanistic and Economic Burden of Patients with Cardiorenal Metabolic Conditions-A Systematic Literature Review
Ferdinand, Keith
Norris, Keith C.
Rodbard, Helena W.
Trujillo, Jennifer
DIABETES, 2023, 72

← 1 2 3 4 5 →